Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced the commencement of a proposed underwritten public offering of 10,000,000 shares of its common stock.
June 1, 2020
· 3 min read